SI
SI
discoversearch

Biotech / Medical : Biotech Valuation

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
From: Ian@SI3/26/2012 4:29:49 PM
of 42341
 
OT: Person who wrote this PR really needs to learn basic English grammar.


Public Release: 26-Mar-2012
Ticagrelor effective at reducing first, as well as recurrent and overall cardiovascular events
New research from Brigham and Women's Hospital shows that the use of ticagrelor not only reduces the time to a first cardiovascular event (the metric used in most trials) but also significantly reduces the time to a second cardiovascular event or death, and reduces total events including cardiovascular death, heart attack, stroke, ischemic events and urgent revascularization.
AstraZeneca
Contact: Lori Shanks
ljshanks@partners.org
617-534-1604
Brigham and Women's Hospital
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.